IP Library Granted Patent US 10,322,996
Granted Patent B2
US 10,322,996 · App. 16/176,215 · Granted Jun 18, 2019

Method for producing N-retinoylcysteic acid alkyl ester

Inventors: Dzianis Babrou (Uppsala, SE); Maryna Budnikava (Uppsala, SE); Mikael Björklund (Uppsala, SE); Julian Aleksov (Lidingö, SE)
Assignee: ARDENIA INVESTMENTS, LTD
C07C403/22C07C403/20C07D301/00C07D301/32C07D303/46C07C2601/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,322,996
App. No.
16/176,215
Granted
Jun 18, 2019
Kind
B2
Abstract

A method for producing derivatives of N-retinoylaminoalkane sulfonic acid, the method comprising providing retinoic acid, chloroformate, aminoalkanesulfonic acid selected from the group consisting of cysteic acid and alkyl ester thereof, cysteinesulfinic acid and alkyl ester thereof, homocysteic acid and alkyl ester thereof, homocysteinesulfinic acid and alkyl esters thereof, taurine and derivatives thereof, and an organic solvent, and a base, mixing said components under substantial absence of oxidizing compounds thereby forming a reaction mixture comprising a liquid phase, wherein the liquid phase is one phase and the derivatives of N-retinoylaminoalkane sulfonic acid are formed in said liquid phase.

Claims (15)

1. A method for producing derivatives of N-retinoylaminoalkane sulfonic acid, the method comprising providing retinoic acid, chloroformate, aminoalkanesulfonic acid selected from the group consisting of cysteic acid and alkyl ester thereof, cysteinesulfinic acid and alkyl ester thereof, homocysteic acid and alkyl ester thereof, homocysteinesulfinic acid and alkyl esters thereof, taurine and derivatives thereof, and an organic solvent, and a base, mixing said components under substantial absence of oxidizing compounds thereby forming a reaction mixture comprising at least a liquid phase, wherein the liquid phase is one phase and the derivatives of N-retinoylaminoalkane sulfonic acid are formed in said liquid phase.

2. The method according to claim 1 , wherein the derivatives of N-retinoylaminoalkane sulfonic acid are selected from N-(13-cis-retinoyl)-cysteic acid alkyl ester and N-(all-trans-retinoyl)-cysteic acid alkyl ester, the retinoic acid is selected from 13-cis-retinoic acid or all-trans-retinoic acid, and the aminoalkane sulfonic acid selected from cysteic acid alkyl ester.

3. The method according to claim 1 , wherein the derivatives of N-retinoylaminoalkane sulfonic acid are selected from the sodium salts of N-(13-cis-retinoyl)-cysteic acid alkyl ester and N-(all-trans-retinoyl)-cysteic acid alkyl ester, the retinoic acid is selected from 13-cis-retinoic acid or all-trans-retinoic acid, and the aminoalkane sulfonic acid selected from cysteic acid alkyl ester.

4. The method according to claim 1 , wherein the derivatives of N-retinoylaminoalkane sulfonic acid are selected from N-(13-cis-retinoyl)-cysteic acid alkyl ester, the retinoic acid is selected from 13-cis-retinoic acid, and the aminoalkane sulfonic acid selected from cysteic acid alkyl ester.

5. The method according to claim 1 , wherein the derivatives of N-retinoylaminoalkane sulfonic acid are selected from the sodium salt of N-(13-cis-retinoyl)-cysteic acid alkyl ester, the retinoic acid is selected from 13-cis-retinoic acid, and the aminoalkane sulfonic acid selected from cysteic acid alkyl ester.

6. The method according to claim 1 , wherein the derivatives of N-retinoylaminoalkane sulfonic acid are selected from N-(all-trans-retinoyl)-cysteic acid alkyl ester, the retinoic acid is selected from all-trans-retinoic acid, and the aminoalkane sulfonic acid selected from cysteic acid alkyl ester.

7. The method according to claim 1 , wherein the derivatives of N-retinoylaminoalkane sulfonic acid are selected from the sodium salt of N-(all-trans-retinoyl)-cysteic acid alkyl ester, the retinoic acid is selected from all-trans-retinoic acid, and the aminoalkane sulfonic acid selected from cysteic acid alkyl ester.

8. The method according to claim 1 , wherein the organic solvent comprises at least an alcohol.

9. The method according to claim 8 , wherein the organic solvent comprises an aprotic solvent and at least an alcohol.

10. The method according to claim 8 , wherein the alcohol comprises from 1 to 10 carbon atoms.

11. The method according to claim 9 , wherein the aprotic solvent is selected from the group consisting of ethers, esters, amides, nitriles and sulfoxides.

12. The method according to claim 11 , wherein the aprotic solvent is an ether.

13. The method according to claim 1 , wherein the base is an amine.

14. The method according to claim 13 , wherein the amine comprises aliphatic groups independent from each other comprising from 1 to 4 carbon atoms.

15. The method according to claim 13 , wherein the base is triethylamine.

Assignments (3)
CHANGE OF NAME Recorded Sep 26, 2022
From: OASMIA PHARMACEUTICAL AB
To: VIVESTO AB
Reel/Frame 061539/0248 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2019
From: ARDENIA INVESTMENTS, LTD.
To: OASMIA PHARMACEUTICAL AB
Reel/Frame 050338/0853 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2019
From: BABROU, DZIANIS; BUDNIKAVA, MARYNA; BJÖRKLUND, MIKAEL; ALEKSOV, JULIAN
To: ARDENIA INVESTMENTS, LTD
Reel/Frame 048976/0311 →
Priority Claims (1)
SE 1551615 · Dec 9, 2015 · national
Continuity (3)
Continuation 16003209 · Jun 8, 2018
Continuation PCTSE2016051238 · Dec 9, 2016
Related Publication 20190127322A1 · May 2, 2019